TNF and herpes zoster: Curtis et al. estimated a higher incidence rate of herpes zoster with tofacitinib (3.57 events per 100 patient-years (95% CI, 2.84–4.43)) than with anti-TNF-α (1.77 (95% CI, 1.34–2.29)) [64].